by | Nov 22, 2022 | Uncategorized
GSK has started the process of withdrawing belantamab mafodotin-blmf from the U.S. market.The FDA requested the action after a confirmatory trial of the multiple myeloma therapy failed to meet requirements specified under the agency’s accelerated approval...
by | Nov 22, 2022 | Uncategorized
Source: Cure Today articles As a part of its “Speaking Out” video series, on behalf of the International Myeloma Foundation, CURE® spoke with their chief medical officer, Dr. Joseph Mikhael about the risk of infection for patients with multiple myeloma. Read...
by | Nov 22, 2022 | Uncategorized
Source: Cure Today articles As a part of its “Speaking Out” video series, on behalf of the International Myeloma Foundation, CURE® spoke with their chief medical officer, Dr. Joseph Mikhael about the precursors to multiple myeloma, MGUS and smoldering myeloma. Read...
by | Nov 22, 2022 | Uncategorized
Source: Cure Today articles As a part of its “Speaking Out” video series, on behalf of the International Myeloma Foundation, CURE® spoke with their chief medical officer, Dr. Joseph Mikhael about disparities in the multiple myeloma space. Read...
by | Nov 22, 2022 | Uncategorized
Source: Cure Today articles As a part of its “Speaking Out” video series, on behalf of the International Myeloma Foundation, CURE® spoke with their chief medical officer, Dr. Joseph Mikhael about clinical trials for patients with multiple myeloma. Read...
by | Nov 21, 2022 | Uncategorized
Source: Cure Today articles As a part of its “Speaking Out” video series, on behalf of the International Myeloma Foundation, CURE® spoke with their vice president of support, Robin Tuohy about the importance of support for patients with multiple myeloma, and their...
